Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2647) 2647
Publication (359) 359
Newsletter (41) 41
Book Review (27) 27
Dissertation (7) 7
Magazine Article (4) 4
Book / eBook (3) 3
Book Chapter (1) 1
Conference Proceeding (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1861) 1861
index medicus (1298) 1298
male (1191) 1191
animals (1129) 1129
quinolines - pharmacokinetics (1105) 1105
pharmacology & pharmacy (994) 994
quinolines - pharmacology (913) 913
female (838) 838
adult (616) 616
quinolines - administration & dosage (610) 610
pharmacokinetics (584) 584
quinolines - therapeutic use (565) 565
fluoroquinolones (541) 541
middle aged (481) 481
rats (448) 448
mice (407) 407
moxifloxacin (340) 340
quinolines - adverse effects (334) 334
dose-response relationship, drug (323) 323
aged (283) 283
quinolines - blood (283) 283
quinolines - chemistry (282) 282
microbiology (280) 280
administration, oral (276) 276
chemistry, medicinal (269) 269
aza compounds - pharmacokinetics (268) 268
oncology (267) 267
infectious diseases (251) 251
research (250) 250
area under curve (228) 228
quinoline (223) 223
adolescent (220) 220
treatment outcome (216) 216
analysis (198) 198
in-vitro (197) 197
drug interactions (195) 195
pharmacology (195) 195
quinolines (195) 195
young adult (194) 194
cancer (193) 193
microbial sensitivity tests (193) 193
aza compounds - administration & dosage (190) 190
drug therapy (190) 190
quinolines - metabolism (189) 189
chromatography, high pressure liquid (187) 187
biological availability (182) 182
ciprofloxacin (172) 172
malaria (172) 172
structure-activity relationship (170) 170
anti-infective agents - pharmacokinetics (162) 162
rats, sprague-dawley (162) 162
time factors (162) 162
levofloxacin (160) 160
double-blind method (155) 155
safety (154) 154
kinetics (151) 151
quinolines - chemical synthesis (151) 151
aza compounds - pharmacology (149) 149
cross-over studies (149) 149
health aspects (148) 148
tissue distribution (144) 144
biochemistry & molecular biology (140) 140
half-life (138) 138
p-glycoprotein (136) 136
drug therapy, combination (134) 134
anti-bacterial agents - pharmacokinetics (127) 127
aza compounds - therapeutic use (127) 127
cell line, tumor (126) 126
drugs (126) 126
chemistry, organic (125) 125
dogs (123) 123
dosage and administration (121) 121
research article (121) 121
efficacy (120) 120
expression (120) 120
resistance (120) 120
toxicology (120) 120
article (119) 119
care and treatment (116) 116
drug resistance (115) 115
pharmacology/toxicology (115) 115
metabolism (114) 114
anti-bacterial agents - pharmacology (113) 113
aza compounds (110) 110
models, biological (109) 109
antimalarials - therapeutic use (106) 106
antineoplastic agents - pharmacology (106) 106
cell line (106) 106
therapy (106) 106
medicine & public health (104) 104
pharmacodynamics (104) 104
parasitic diseases (103) 103
biotransformation (102) 102
anti-infective agents - pharmacology (99) 99
antibiotics (99) 99
clinical trials (99) 99
in vitro techniques (98) 98
medicine (97) 97
aged, 80 and over (96) 96
drug administration schedule (96) 96
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2665) 2665
French (9) 9
Chinese (6) 6
Russian (6) 6
German (4) 4
Japanese (4) 4
Spanish (4) 4
Hungarian (2) 2
Czech (1) 1
Dutch (1) 1
Italian (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children
by Zhou, Wangda and Johnson, Trevor N and Bui, Khanh H and Cheung, S.Y. Amy and Li, Jianguo and Xu, Hongmei and Al‐Huniti, Nidal and Zhou, Diansong
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 07/2018, Volume 104, Issue 1, pp. 188 - 200
The accuracy of physiologically based pharmacokinetic (PBPK) model prediction in children, especially those younger than 2 years old, has not been... 
CLEARANCE | TISSUE DISTRIBUTION | IN-VIVO | VOLUME | ONTOGENY | PROTON PUMP INHIBITORS | PHARMACOLOGY & PHARMACY | PHARMACODYNAMICS | SIMULATION | DESLORATADINE | EXPOSURE | Humans | Anti-Asthmatic Agents - metabolism | Child, Preschool | Cytochrome P-450 Enzyme System - metabolism | Sufentanil - metabolism | Bronchodilator Agents - metabolism | Quinolines - pharmacokinetics | Theophylline - pharmacokinetics | Esomeprazole - metabolism | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Ondansetron - metabolism | Child | Cytochrome P-450 CYP2C9 - metabolism | Histamine H1 Antagonists, Non-Sedating - pharmacokinetics | Infant, Newborn | Itraconazole - metabolism | Serotonin Antagonists - pharmacokinetics | Tramadol - pharmacokinetics | Theophylline - metabolism | Cytochrome P-450 CYP3A - metabolism | Models, Biological | Proton Pump Inhibitors - metabolism | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Cytochrome P-450 CYP2D6 - metabolism | Serotonin Antagonists - metabolism | Analgesics, Opioid - metabolism | Diclofenac - metabolism | Lansoprazole - pharmacokinetics | Loratadine - pharmacokinetics | Sufentanil - pharmacokinetics | Infant | Anti-Asthmatic Agents - pharmacokinetics | Itraconazole - pharmacokinetics | Antifungal Agents - pharmacokinetics | Antifungal Agents - metabolism | Loratadine - metabolism | Cytochrome P-450 CYP2C8 - metabolism | Lansoprazole - metabolism | Acetates - metabolism | Esomeprazole - pharmacokinetics | Cytochrome P-450 CYP1A2 - metabolism | Ondansetron - pharmacokinetics | Tramadol - metabolism | Diclofenac - pharmacokinetics | Quinolines - metabolism | Pharmaceutical Preparations - metabolism | Proton Pump Inhibitors - pharmacokinetics | Bronchodilator Agents - pharmacokinetics | Analgesics, Opioid - pharmacokinetics | Cytochrome P-450 CYP2C19 - metabolism | Loratadine - analogs & derivatives | Histamine H1 Antagonists, Non-Sedating - metabolism | Pharmacokinetics | Acetates - pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Saliva versus plasma pharmacokinetics: Theory and application of a salivary excretion classification system
by Idkaidek, Nasir and Arafat, Tawfiq
Molecular Pharmaceutics, ISSN 1543-8384, 08/2012, Volume 9, Issue 8, pp. 2358 - 2363
The aims of this work were to study pharmacokinetics of randomly selected drugs in plasma and saliva samples in healthy human volunteers, and to introduce a... 
Salivary Excretion Classification System | effective permeability | pharmacokinetics | protein binding | bioequivalence | SimCYP | MEDICINE, RESEARCH & EXPERIMENTAL | RELATIVE BIOAVAILABILITY | PERMEABILITY | CLINICAL PHARMACOKINETICS | BIOLOGICAL FLUID | DRUGS | PHARMACOLOGY & PHARMACY | Quinolines - blood | Acetates - blood | Fluorobenzenes - pharmacokinetics | Hydrochlorothiazide - pharmacokinetics | Triazoles - blood | Piroxicam - blood | Azithromycin - blood | Humans | Losartan - blood | Saliva - secretion | Male | Naphthalenes - blood | Benzhydryl Compounds - blood | Fluorobenzenes - pharmacology | Quinolines - pharmacokinetics | Sulfonamides - blood | Azithromycin - pharmacokinetics | Tolterodine Tartrate | Female | Triazoles - pharmacokinetics | Naphthalenes - pharmacokinetics | Piroxicam - analogs & derivatives | Sitagliptin Phosphate | Hydrochlorothiazide - blood | Losartan - pharmacokinetics | Benzhydryl Compounds - pharmacokinetics | Metformin - blood | Cresols - blood | Phenylpropanolamine - blood | Metformin - pharmacokinetics | Rosuvastatin Calcium | Cloxacillin - pharmacokinetics | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Cinacalcet Hydrochloride | Cloxacillin - blood | Saliva - metabolism | Pyrazines - pharmacokinetics | Piroxicam - pharmacokinetics | Pyrimidines - pharmacokinetics | Cresols - pharmacokinetics | Anthraquinones - blood | Anthraquinones - pharmacokinetics | Phenylpropanolamine - pharmacokinetics | Pyrazines - blood | Acetates - pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization
by Elisabet I. Nielsen and Otto Cars and Lena E. Friberg
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 10/2011, Volume 55, Issue 10, pp. 4619 - 4630
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
VITRO DYNAMIC-MODEL | STREPTOCOCCUS-PNEUMONIAE | PHARMACODYNAMIC MODEL | POPULATION PHARMACOKINETICS | PSEUDOMONAS-AERUGINOSA | ADAPTIVE RESISTANCE | IN-VIVO | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | MONTE-CARLO SIMULATIONS | AMINOGLYCOSIDE ANTIBIOTICS | RESPIRATORY-TRACT INFECTIONS | Fluoroquinolones | Aza Compounds - pharmacokinetics | Area Under Curve | Erythromycin - pharmacology | Escherichia coli - drug effects | Humans | Cefuroxime - pharmacology | Aza Compounds - pharmacology | Quinolines - pharmacology | Microbial Sensitivity Tests | Quinolines - pharmacokinetics | Anti-Bacterial Agents - therapeutic use | Gentamicins - pharmacology | Computer Simulation | Vancomycin - pharmacology | Streptococcus pyogenes - drug effects | Gentamicins - pharmacokinetics | Penicillin G - pharmacology | Erythromycin - pharmacokinetics | Cefuroxime - pharmacokinetics | Vancomycin - pharmacokinetics | Anti-Bacterial Agents - pharmacokinetics | Anti-Bacterial Agents - pharmacology | Anti-Bacterial Agents - administration & dosage | Penicillin G - pharmacokinetics | Drugs | Subpopulations | Pharmacodynamics | Gentamicin | Benzylpenicillin | Erythromycin | Moxifloxacin | Regression analysis | Vancomycin | Drug development | Cefuroxime | Antibiotics | Minimum inhibitory concentration | Models | Pharmacokinetics | Experimental Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Application of physiologically based pharmacokinetic modeling to the understanding of bosutinib pharmacokinetics: Prediction of drug-drug and drug-disease interactions
by Ono, Chiho and Hsyu, Poe-Hirr and Abbas, Richat and Loi, Cho-Ming and Yamazaki, Shinji
Drug Metabolism and Disposition, ISSN 0090-9556, 04/2017, Volume 45, Issue 4, pp. 390 - 398
Bosutinib is an orally available Src/Abl tyrosine kinase inhibitor indicated for the treatment of patients with Philadelphia chromosome-positive chronic... 
LIVER-CIRRHOSIS | SAFETY | KETOCONAZOLE | PHARMACOLOGY & PHARMACY | HEPATIC IMPAIRMENT | SIMULATION | INHIBITOR | DISCOVERY | EXPOSURE | CHRONIC-RENAL-FAILURE | Protein Kinase Inhibitors - pharmacokinetics | Rifampin - pharmacokinetics | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Administration, Oral | Area Under Curve | Humans | src-Family Kinases - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Ketoconazole - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Treatment Outcome | Aniline Compounds - pharmacokinetics | Quinolines - administration & dosage | Nitriles - pharmacokinetics | Nitriles - administration & dosage | Quinolines - pharmacokinetics | Protein Kinase Inhibitors - administration & dosage | Drug Interactions | Cytochrome P-450 CYP3A - metabolism | Models, Biological | Computer Simulation | Cytochrome P-450 CYP3A Inducers - pharmacokinetics | Aniline Compounds - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib
by Abbas, Richat and Hsyu, Poe-Hirr
Clinical Pharmacokinetics, ISSN 0312-5963, 10/2016, Volume 55, Issue 10, pp. 1191 - 1204
Chronic myeloid leukemia (CML) is a clonal myeloproliferative stem cell disorder. Bosutinib is an oral, once-daily SRC/ABL tyrosine kinase inhibitor with very... 
CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | CHRONIC-PHASE | HEALTHY-SUBJECTS | TYROSINE KINASE | BCR-ABL | IMATINIB | CHROMOSOME-POSITIVE LEUKEMIAS | PHARMACOLOGY & PHARMACY | KINASE INHIBITOR | CHRONIC MYELOID-LEUKEMIA | Nitriles - pharmacology | Area Under Curve | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Half-Life | Metabolic Clearance Rate | Nitriles - pharmacokinetics | Intestinal Absorption | Quinolines - pharmacology | Dose-Response Relationship, Drug | Quinolines - pharmacokinetics | Liver Failure - metabolism | Drug Interactions | Electrocardiography | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Protein Kinase Inhibitors - pharmacokinetics | Aniline Compounds - pharmacology | Clinical Trials as Topic | Renal Insufficiency - metabolism | Aniline Compounds - pharmacokinetics | Asian Continental Ancestry Group | Cytochrome P-450 CYP3A - metabolism | Protein Binding | Protein Kinase Inhibitors - pharmacology | Quinolines - therapeutic use | Aniline Compounds - therapeutic use | Nitriles - therapeutic use | Care and treatment | Dosage and administration | Pharmacology | Research | Chronic myeloid leukemia | Diagnosis | Pharmacokinetics | Bosutinib | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Transporter‐Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug–Drug Interactions of Montelukast
by Varma, MV and Kimoto, E and Scialis, R and Bi, Y and Lin, J and Eng, H and Kalgutkar, AS and El‐Kattan, AF and Rodrigues, AD and Tremaine, LM
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 03/2017, Volume 101, Issue 3, pp. 406 - 415
Montelukast, a leukotriene receptor antagonist commonly prescribed for treatment of asthma, is primarily metabolized by cytochrome P450 (CYP)2C8, and has been... 
SANDWICH CULTURE | GEMFIBROZIL | IN-VITRO | INHIBITION | PLASMA-CONCENTRATIONS | QUANTITATIVE PREDICTION | MECHANISTIC MODELS | HUMANS | PHARMACOLOGY & PHARMACY | CYNOMOLGUS MONKEYS | RECEPTOR ANTAGONIST | Organic Anion Transporters - antagonists & inhibitors | Cytochrome P-450 CYP2C8 - drug effects | Liver - metabolism | Rats | Gemfibrozil - pharmacology | Hepatocytes - metabolism | Organic Anion Transporters - metabolism | Quinolines - pharmacology | Haplorhini | Dose-Response Relationship, Drug | Quinolines - pharmacokinetics | Nucleic Acid Synthesis Inhibitors | Animals | Cytochrome P-450 CYP3A Inhibitors - metabolism | Models, Biological | Solute Carrier Organic Anion Transporter Family Member 1b1 - antagonists & inhibitors | Clarithromycin - pharmacokinetics | Acetates - pharmacology | Cytochrome P-450 CYP2C8 - metabolism | Rifampin - pharmacology | Acetates - pharmacokinetics | Care and treatment | Usage | Montelukast | Dosage and administration | Research | Drug therapy | Pharmacokinetics | Asthma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial
by Ruslami, Rovina, PhD and Ganiem, A Rizal, MD and Dian, Sofiati, MD and Apriani, Lika, MSc and Achmad, Tri Hanggono, Prof and van der Ven, Andre J, Prof and Borm, George, Prof and Aarnoutse, Rob E, PhD and van Crevel, Reinout, Dr
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 1, pp. 27 - 35
Summary Background Intensified antibiotic treatment might improve the outcome of tuberculous meningitis. We assessed pharmacokinetics, safety, and survival... 
Infectious Disease | MYCOBACTERIUM-TUBERCULOSIS | ETHAMBUTOL | INFECTIOUS DISEASES | IN-VITRO | PHARMACOKINETICS | LEVOFLOXACIN | PULMONARY TUBERCULOSIS | INFECTION | DRUG-RESISTANCE | CEREBROSPINAL-FLUID | CIPROFLOXACIN | Fluoroquinolones | Aza Compounds - pharmacokinetics | Antitubercular Agents - adverse effects | Rifampin - pharmacokinetics | Antibiotics, Antitubercular - adverse effects | Follow-Up Studies | Humans | Middle Aged | Aza Compounds - adverse effects | Male | Quinolines - administration & dosage | Quinolines - pharmacokinetics | Young Adult | Drug Therapy, Combination - adverse effects | Rifampin - adverse effects | Adult | Female | Rifampin - administration & dosage | Antibiotics, Antitubercular - administration & dosage | Aza Compounds - administration & dosage | Anti-Infective Agents - adverse effects | Antibiotics, Antitubercular - pharmacokinetics | Tuberculosis, Meningeal - drug therapy | Drug Administration Schedule | Drug Therapy, Combination - methods | Anti-Infective Agents - administration & dosage | Antitubercular Agents - pharmacokinetics | Anti-Infective Agents - pharmacokinetics | Adolescent | Antitubercular Agents - administration & dosage | Tuberculosis, Meningeal - metabolism | Quinolines - adverse effects | Indonesia | Tuberculosis | Meningitis | Dosage and administration | Product development | Moxifloxacin | Universities and colleges | Rifampin | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma
by Ikeda, Masafumi and Okusaka, Takuji and Mitsunaga, Shuichi and Ueno, Hideki and Tamai, Toshiyuki and Suzuki, Takuya and Hayato, Seiichi and Kadowaki, Tadashi and Okita, Kiwamu and Kumada, Hiromitsu
Clinical Cancer Research, ISSN 1078-0432, 03/2016, Volume 22, Issue 6, pp. 1385 - 1394
Purpose: To determine the maximum tolerable dose (MTD), safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of lenvatinib in patients with... 
SURVIVAL | E7080 | PLACEBO | ONCOLOGY | PHASE-III | TOXICITY | SORAFENIB | INHIBITOR | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Liver Neoplasms - mortality | Quinolines - pharmacokinetics | Neoplasm Metastasis | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Female | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacokinetics | Phenylurea Compounds - pharmacokinetics | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Phenylurea Compounds - therapeutic use | Treatment Outcome | Combined Modality Therapy | Magnetic Resonance Imaging | Retreatment | Carcinoma, Hepatocellular - pathology | Aged | Quinolines - therapeutic use | Neoplasm Staging | Quinolines - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Population Pharmacokinetic and Concentration-QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies
by Florian, Jeffry A and Tornøe, Christoffer W and Brundage, Richard and Parekh, Ameeta and Garnett, Christine E
Journal of Clinical Pharmacology, ISSN 0091-2700, 08/2011, Volume 51, Issue 8, pp. 1152 - 1162
To increase our understanding of important subject characteristics and design variables affecting the performance of oral moxifloxacin in thorough QT studies,... 
Population pharmacokinetics | QT prolongation | exposure-response modeling | thorough QT studies | ICH E14 | moxifloxacin | WOMEN | INTERVAL PROLONGATION | TRAFFICKING | PHARMACOLOGY & PHARMACY | QT/QTC | QUINIDINE | Fluoroquinolones | Aza Compounds - pharmacokinetics | Quinolines - blood | Drugs, Investigational - adverse effects | Anti-Infective Agents - blood | United States | Humans | Middle Aged | Drugs, Investigational - pharmacokinetics | Aza Compounds - adverse effects | Male | Metabolic Clearance Rate | Quinolines - administration & dosage | Drugs, Investigational - analysis | Intestinal Absorption | Delayed-Action Preparations - administration & dosage | Quinolines - pharmacokinetics | Young Adult | Delayed-Action Preparations - pharmacokinetics | Adult | Aza Compounds - blood | Female | United States Food and Drug Administration | Aza Compounds - administration & dosage | Anti-Infective Agents - adverse effects | Administration, Oral | Electrocardiography - drug effects | Clinical Trials as Topic | Animals | Anti-Infective Agents - administration & dosage | Delayed-Action Preparations - adverse effects | Models, Biological | Anti-Infective Agents - pharmacokinetics | Adolescent | Drugs, Investigational - administration & dosage | Aged | Quinolines - adverse effects | Physiological aspects | Moxifloxacin | Research | Demographic aspects | Pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus
by Sandrine Lemaire and Paul M. Tulkens and Françoise Van Bambeke
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 02/2011, Volume 55, Issue 2, pp. 649 - 658
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
LISTERIA-MONOCYTOGENES | CYSTIC-FIBROSIS PATIENT | IN-VITRO | LEGIONELLA-PNEUMOPHILA | HUMAN THP-1 MACROPHAGES | ANTIBACTERIAL ACTIVITIES | J774 MACROPHAGES | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | QUINOLONES CIPROFLOXACIN | CELLULAR UPTAKE | PHARMACODYNAMIC EVALUATION | Fluoroquinolones - chemistry | Aza Compounds - pharmacokinetics | Anti-Infective Agents - pharmacology | Humans | Monocytes - metabolism | Aza Compounds - pharmacology | Fluoroquinolones - pharmacokinetics | Quinolines - pharmacology | Microbial Sensitivity Tests | Quinolines - pharmacokinetics | Anti-Infective Agents - chemistry | Staphylococcal Infections - microbiology | Culture Media - chemistry | Staphylococcus aureus - metabolism | Cell Line | Monocytes - microbiology | Quinolines - chemistry | Aza Compounds - chemistry | Macrophages - metabolism | Animals | Models, Biological | Anti-Infective Agents - pharmacokinetics | Fluoroquinolones - pharmacology | Mice | Staphylococcus aureus - drug effects | Hydrogen-Ion Concentration | Susceptibility
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions
by Maria C. Kjellsson and Laura E. Via and Anne Goh and Danielle Weiner and Kang Min Low and Steven Kern and Goonaseelan Pillai and Clifton E. Barry III and Véronique Dartois and Medicinska och farmaceutiska vetenskapsområdet and Institutionen för farmaceutisk biovetenskap and Uppsala universitet and Farmaceutiska fakulteten
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 01/2012, Volume 56, Issue 1, pp. 446 - 457
OA  Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley... 
MYCOBACTERIUM-TUBERCULOSIS | NONREPLICATING PERSISTENCE | FIBEROPTIC BRONCHOSCOPY | INTRAPULMONARY CONCENTRATIONS | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | EPITHELIAL LINING FLUID | MODEL | CEREBROSPINAL-FLUID | CLINICAL PHARMACOKINETICS | MOXIFLOXACIN | TISSUE CONCENTRATIONS | Fluoroquinolones | Aza Compounds - pharmacokinetics | Lung - microbiology | Quinolines - blood | Tissue Extracts - chemistry | Tuberculosis, Pulmonary - microbiology | Rifampin - pharmacokinetics | Rifampin - blood | Humans | Isoniazid - blood | Lung - chemistry | Biological Availability | Tuberculosis, Pulmonary - drug therapy | Mycobacterium tuberculosis - drug effects | Quinolines - pharmacokinetics | Tuberculosis, Pulmonary - blood | Aza Compounds - blood | Female | Disease Models, Animal | Granuloma - microbiology | Rabbits | Drug Administration Schedule | Isoniazid - pharmacokinetics | Pyrazinamide - pharmacokinetics | Pyrazinamide - blood | Antitubercular Agents - blood | Animals | Antitubercular Agents - pharmacokinetics | Lung - drug effects | Mycobacterium tuberculosis - growth & development | Pharmacology | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Duration of drug action of dopamine D2 agonists in mice with 6-hydroxydopamine-induced lesions
by Tsuchioka, Akihiro and Oana, Fumiki and Suzuki, Takayuki and Yamauchi, Yuji and Ijiro, Tomoyuki and Kaidoh, Kouichi and Hiratochi, Masahiro
NeuroReport, ISSN 0959-4965, 12/2015, Volume 26, Issue 18, pp. 1126 - 1132
Although 6-hydroxydopamine-induced (6-OHDA-induced) rats are a well-known Parkinson’s disease model, the effects of dopamine D2 agonists in mice with... 
6-hydroxydopamine | Duration of drug action | Mice | Parkinson's disease | Dopamine agonist | BEHAVIOR | RATS | dopamine agonist | mice | NEUROSCIENCES | ROTIGOTINE | D-3 RECEPTORS | INJECTION | duration of drug action | MOUSE MODEL | ANIMAL-MODELS | ANTAGONISTS | PARKINSONS-DISEASE | Apomorphine - pharmacokinetics | Parkinsonian Disorders - psychology | Receptors, Dopamine D2 - agonists | Injections, Intraventricular | Dopamine Agonists - pharmacokinetics | Motor Activity - drug effects | Tetrahydronaphthalenes - pharmacokinetics | Male | Parkinsonian Disorders - chemically induced | Benzothiazoles - pharmacokinetics | Antiparkinson Agents - pharmacokinetics | Ergolines - pharmacokinetics | Quinolines - pharmacokinetics | Thiophenes - pharmacokinetics | Animals | Oxidopamine - pharmacology | Parkinsonian Disorders - pathology | Corpus Striatum - drug effects | Indoles - pharmacokinetics | Azepines - pharmacokinetics | Corpus Striatum - pathology | Disease Models, Animal
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
by Ford, John and Lawson, Matt and Fowler, David and Maruyama, Nobuko and Mito, Seiji and Tomiyasu, Koichi and Kinoshita, Shuji and Suzuki, Chisa and Kawaguchi, Atsuhiro and Round, Patrick and Boyce, Malcolm and Warrington, Steve and Weber, Werner and van Deventer, Sander and Kastelein, John J. P
British journal of clinical pharmacology, ISSN 0306-5251, 2014, Volume 78, Issue 3, pp. 498 - 508
Two double-blind, randomized studies were conducted to assess the tolerability, pharmacokinetics and pharmacodynamics of oral TA-8995, a new cholesteryl ester... 
coronary disease | cholesterol | apolipoproteins | cardiovascular diseases | hypercholesterolaemia | MYOCARDIAL-INFARCTION | SAFETY | RISK | TORCETRAPIB | VASCULAR-DISEASE | LDL CHOLESTEROL | HDL | CARDIOVASCULAR-DISEASE | PHARMACOLOGY & PHARMACY | CORONARY-HEART-DISEASE | LIPOPROTEIN(A) LEVELS | Cholesterol Ester Transfer Proteins - antagonists & inhibitors | Double-Blind Method | Humans | Middle Aged | Half-Life | European Continental Ancestry Group | Male | Quinolines - administration & dosage | Quinolines - pharmacology | Dose-Response Relationship, Drug | Quinolines - pharmacokinetics | Young Adult | Asian Continental Ancestry Group | Adolescent | Cholesterol, HDL - blood | Electrocardiography | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia | Low density lipoproteins | Analysis | Electrocardiogram | Apolipoproteins | Coronary heart disease | Lipoprotein A | Pharmacodynamics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights